1. The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice. Ceddia RP, Lee D, Maulis MF, Carboneau BA, Threadgill DW, Poffenberger G, Milne G, Boyd KL, Powers AC, McGuinness OP, Gannon M, Breyer RM (2016) Endocrinology 157(1): 220-32
    › Primary publication · 26485614 (PubMed) · PMC4701878 (PubMed Central)
  2. EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. Lu A, Zuo C, He Y, Chen G, Piao L, Zhang J, Xiao B, Shen Y, Tang J, Kong D, Alberti S, Chen D, Zuo S, Zhang Q, Yan S, Fei X, Yuan F, Zhou B, Duan S, Yu Y, Lazarus M, Su Y, Breyer RM, Funk CD, Yu Y (2015) J Clin Invest 125(3): 1228-42
    › Primary publication · 25664856 (PubMed) · PMC4362262 (PubMed Central)
  3. Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor. Natarajan C, Hata AN, Hamm HE, Zent R, Breyer RM (2013) Mol Pharmacol 83(1): 206-16
    › Primary publication · 23087260 (PubMed) · PMC3533480 (PubMed Central)
  4. Differential stem- and progenitor-cell trafficking by prostaglandin E2. Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF, Pelus LM (2013) Nature 495(7441): 365-9
    › Primary publication · 23485965 (PubMed) · PMC3606692 (PubMed Central)
  5. Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere. Downey JD, Saleh SA, Bridges TM, Morrison RD, Daniels JS, Lindsley CW, Breyer RM (2013) Bioorg Med Chem Lett 23(1): 37-41
    › Primary publication · 23218714 (PubMed) · PMC3534858 (PubMed Central)
  6. Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q, Shen Y, Xiong L, Breyer RM, Lazarus M, Funk CD, Yu Y (2013) Circ Res 113(2): 104-14
    › Primary publication · 23595951 (PubMed) · PMC4219358 (PubMed Central)
  7. Correction to CHOBIMALT: A Cholesterol-Based Detergent. Howell SC, Fraser NJ, Mittal R, Huang L, Travis B, Breyer RM, Sanders CR (2013) Biochemistry 52(2): 445
    › Primary publication · 23289860 (PubMed) · PMC3560918 (PubMed Central)
  8. Prostaglandin I2 signaling drives Th17 differentiation and exacerbates experimental autoimmune encephalomyelitis. Zhou W, Dowell DR, Huckabee MM, Newcomb DC, Boswell MG, Goleniewska K, Lotz MT, Toki S, Yin H, Yao S, Natarajan C, Wu P, Sriram S, Breyer RM, Fitzgerald GA, Peebles RS (2012) PLoS One 7(5): e33518
    › Primary publication · 22590492 (PubMed) · PMC3349674 (PubMed Central)
  9. Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice. Tanaka K, Furuyashiki T, Kitaoka S, Senzai Y, Imoto Y, Segi-Nishida E, Deguchi Y, Breyer RM, Breyer MD, Narumiya S (2012) J Neurosci 32(12): 4319-29
    › Primary publication · 22442093 (PubMed) · PMC3784244 (PubMed Central)
  10. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Shi J, Wang Q, Johansson JU, Liang X, Woodling NS, Priyam P, Loui TM, Merchant M, Breyer RM, Montine TJ, Andreasson K (2012) Ann Neurol 72(5): 788-98
    › Primary publication · 22915243 (PubMed) · PMC3509238 (PubMed Central)